Skip to main content
SpringerLink
Log in
Book cover

Allergy and Asthma pp 1–14Cite as

Asthma Phenotypes and Biomarkers

  • Living reference work entry
  • First Online:

  • 238 Accesses

Abstract

For many years asthma has been described as a single disease. However, asthma is a heterogeneous syndrome with complex pathophysiology contributing to numerous clinical phenotypes. Despite various treatments a large proportion of patients remain uncontrolled or poorly controlled. Understanding the underlying inflammatory process in asthma is key for stratification of patients toward personalized therapy. Recently described inflammatory pathways include T2-high and T2-low or non-T2 inflammation. Clinically, T2-high inflammation is associated with atopic/allergic disease with increased evidence of eosinophils in the airway and the peripheral blood, whereas T2-low inflammation is correlated with neutrophilic or paucigranulocytic cells in the airways. Several biomarkers have been identified for T2-high inflammation; however, their utility is limited. Linking the clinical phenotypes to the underlying molecular biology will enhance the successful development of personalized therapies for asthma in the future.

This is a preview of subscription content, log in via an institution.

References

  • Alam R, Good J, Rollins D, Verma M, Chu H, Pham T-H, et al. Airway and serum biochemical correlates of refractory neutrophilic asthma. J Allergy Clin Immunol. 2017;140(4):1004–14.e13.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Barnes PJ. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol. 2015;136(3):531–45.

    PubMed  Google Scholar 

  • Bellini A, Marini MA, Bianchetti L, Barczyk M, Schmidt M, Mattoli S. Interleukin (IL)-4, IL-13, and IL-17A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients. Mucosal Immunol. 2012;5(2):140–9.

    CAS  PubMed  Google Scholar 

  • Berry A, Busse WW. Biomarkers in asthmatic patients: has their time come to direct treatment? J Allergy Clin Immunol. 2016;137(5):1317–24.

    PubMed  Google Scholar 

  • Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–98.

    PubMed  Google Scholar 

  • Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013a;188(11):1294–302.

    CAS  PubMed  Google Scholar 

  • Busse W, Spector S, Rosen K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013b;132(2):485–6.e11.

    PubMed  Google Scholar 

  • Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, et al. Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther. 2018;35:737.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cabon Y, Molinari N, Marin G, Vachier I, Gamez AS, Chanez P, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47(1):129–38.

    CAS  PubMed  Google Scholar 

  • Caggiano S, Cutrera R, Di Marco A, Turchetta A. Exercise-induced bronchospasm and allergy. Front Pediatr. 2017;5:131.

    PubMed  PubMed Central  Google Scholar 

  • Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–90.

    CAS  PubMed  Google Scholar 

  • Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66.

    CAS  PubMed  Google Scholar 

  • Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486.

    CAS  PubMed  Google Scholar 

  • Centers for Disease Control and Prevention: Data, Statistics, and Surveillance. AsthmaStats. 2015. Available from http://www.cdc.gov/asthma/asthma_stats/default.htm.

  • CINQAIR (reslizumab) prescribing information. Available from http://www.cinqair.com/.

  • Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12): 1088–98.

    CAS  PubMed  Google Scholar 

  • Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799.

    PubMed  Google Scholar 

  • DUPIXENT. Dupilumab prescribing information. Available from https://www.dupixent.com/.

  • Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fasenra (benralizumab) prescribing information. Available from https://www.fasenrahcp.com/.

  • Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. The J Allergy Clin Immunol 2011;127(2):382–9.e1–13.

    Google Scholar 

  • Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–71.

    CAS  PubMed  Google Scholar 

  • Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–24.

    PubMed  PubMed Central  Google Scholar 

  • Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–11.

    CAS  PubMed  Google Scholar 

  • Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748–56.

    PubMed  PubMed Central  Google Scholar 

  • Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010;125(5):1028–36.e13.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2(5):525–36.e1.

    PubMed  Google Scholar 

  • Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56.

    CAS  PubMed  Google Scholar 

  • Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–96.e5.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Leiria LOS, Martins MA, Saad MJA. Obesity and asthma: beyond TH2 inflammation. Metabolism. 2015;64(2): 172–81.

    CAS  PubMed  Google Scholar 

  • Liu W, Liu S, Verma M, Zafar I, Good JT, Rollins D, et al. Mechanism of TH2/TH17-predominant and neutrophilic TH2/TH17-low subtypes of asthma. J Allergy Clin Immunol. 2017;139(5):1548–58.e4.

    CAS  PubMed  Google Scholar 

  • Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. Respir Med. 2017;124:36–43.

    PubMed  Google Scholar 

  • Mehta V, Stokes JR, Berro A, Romero FA, Casale TB. Time-dependent effects of inhaled corticosteroids on lung function, bronchial hyperresponsiveness, and airway inflammation in asthma. Ann Allergy Asthma Immunol. 2009;103(1):31–7.

    CAS  PubMed  Google Scholar 

  • Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004;113(1):101–8.

    PubMed  Google Scholar 

  • Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2): 405–13.

    PubMed  PubMed Central  Google Scholar 

  • Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4): 315–23.

    PubMed  Google Scholar 

  • Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14–20.

    PubMed  Google Scholar 

  • NUCALA (mepolizumab). Available from https://www.gsksource.com/pharma/content/gsk/source/us/en/brands/nucala/pi.html?cc=F736CF99B6F1&pid=.

  • Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207.

    PubMed  Google Scholar 

  • Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–9.

    CAS  PubMed  Google Scholar 

  • Pelaia G, Canonica GW, Matucci A, Paolini R, Triggiani M, Paggiaro P. Targeted therapy in severe asthma today: focus on immunoglobulin E. Drug Des Devel Ther. 2017;11:1979–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Petsky HL, Kew KM, Turner C, Chang AB. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016;9:Cd011440.

    PubMed  Google Scholar 

  • Phenotype. Merriam-Webster.com. Available from https://www.merriam-webster.com/dictionary/phenotype.

  • Pijnenburg MW, Bakker EM, Lever S, Hop WC, De Jongste JC. High fractional concentration of nitric oxide in exhaled air despite steroid treatment in asthmatic children. Clin Exp Allergy. 2005;35(7):920–5.

    CAS  PubMed  Google Scholar 

  • Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11): 849–58.

    PubMed  Google Scholar 

  • Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475.

    CAS  PubMed  Google Scholar 

  • Raffray L, Guillevin L. Treatment of eosinophilic granulomatosis with polyangiitis: a review. Drugs. 2018;78:809.

    CAS  PubMed  Google Scholar 

  • Rank MA, Ochkur SI, Lewis JC, Teaford HG 3rd, Wesselius LJ, Helmers RA, et al. Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia. Allergy. 2016;71(4):567–70.

    CAS  PubMed  Google Scholar 

  • Rodriguez-Jimenez JC, Moreno-Paz FJ, Teran LM, Guani-Guerra E. Aspirin exacerbated respiratory disease: current topics and trends. Respir Med. 2018;135:62–75.

    PubMed  Google Scholar 

  • Suzuki Y, Saito J, Kikuchi M, Uematsu M, Fukuhara A, Sato S, et al. Sputum-to-serum hydrogen sulfide ratio as a novel biomarker of predicting future risks of asthma exacerbation. Clin Exp Allergy. 2018;48:1155.

    CAS  PubMed  Google Scholar 

  • Tabatabaian F, Ledford DK. Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history. J Asthma Allergy. 2018;11:53–61.

    PubMed  PubMed Central  Google Scholar 

  • Tabatabaian F, Ledford DK, Casale TB. Biologic and new therapies in asthma. Immunol Allergy Clin N Am. 2017;37(2):329–43.

    Google Scholar 

  • Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore WC, et al. Baseline features of the severe asthma research program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract. 2018;6(2):545–54.e4.

    PubMed  Google Scholar 

  • Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5): 716–25.

    CAS  PubMed  Google Scholar 

  • Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66.

    CAS  PubMed  Google Scholar 

  • Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.

    CAS  PubMed  Google Scholar 

  • Wilhelm CP, Chipps BE. Bronchial thermoplasty: a review of the evidence. Ann Allergy Asthma Immunol. 2016;116(2):92–8.

    PubMed  Google Scholar 

  • Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A. 2007;104(40):15858–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  • XOLAIR (omalizumab) prescribing information. Available from http://www.xolair.com/allergic-asthma/hcp/.

Download references

Author information

Authors and Affiliations

  1. Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA

    Farnaz Tabatabaian

Authors
  1. Farnaz Tabatabaian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Farnaz Tabatabaian .

Editor information

Editors and Affiliations

  1. Milton S Hershey Med Ctr, Penn State University Milton S Hershey Med Ctr, Hershey, PA, USA

    Timothy Craig

  2. Suite 502, Allergy, Asthma and Immunology Suite 502, Tampa, FL, USA

    Dennis K. Ledford

Section Editor information

  1. Division of Allergy & Immunology, Dept. of Internal Medicine, University of South Florida Morsani College of Medicine, James A Haley Veterans' Hospital, Asthma and Immunology Associates of Tampa Bay, Tampa, Florida, USA

    Dennis K. Ledford

  2. Department of Medicine and Pediatrics, Penn State College of Medicine, Hershey, PA, USA

    Timothy Craig DO

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Tabatabaian, F. (2018). Asthma Phenotypes and Biomarkers. In: Craig, T., Ledford, D. (eds) Allergy and Asthma. Springer, Cham. https://doi.org/10.1007/978-3-319-58726-4_12-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-58726-4_12-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-58726-4

  • Online ISBN: 978-3-319-58726-4

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation